Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:ENTO NASDAQ:LSB NASDAQ:SYBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$3.45+2.1%$3.19$2.00▼$5.00$16.07M2.25917,641 shs105,363 shsENTOEntero Therapeutics$2.48+6.9%$1.72$0.84▼$2.95$3.94M0.89894,067 shs81,880 shsLSBLakeShore Biopharma$0.83-0.4%$0.91$0.59▼$8.60$17.32M0.56123,058 shs135,364 shsSYBXSynlogic$1.50+3.0%$1.44$0.90▼$1.96$17.60M0.5426,175 shs31,437 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-6.37%-7.65%+6.29%+21.58%+27.28%ENTOEntero Therapeutics-11.79%-15.33%+111.93%+35.58%+93.33%LSBLakeShore Biopharma+0.36%+1.89%+19.57%-15.45%-81.40%SYBXSynlogic+0.68%+1.37%+5.71%+21.31%+0.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$3.45+2.1%$3.19$2.00▼$5.00$16.07M2.25917,641 shs105,363 shsENTOEntero Therapeutics$2.48+6.9%$1.72$0.84▼$2.95$3.94M0.89894,067 shs81,880 shsLSBLakeShore Biopharma$0.83-0.4%$0.91$0.59▼$8.60$17.32M0.56123,058 shs135,364 shsSYBXSynlogic$1.50+3.0%$1.44$0.90▼$1.96$17.60M0.5426,175 shs31,437 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-6.37%-7.65%+6.29%+21.58%+27.28%ENTOEntero Therapeutics-11.79%-15.33%+111.93%+35.58%+93.33%LSBLakeShore Biopharma+0.36%+1.89%+19.57%-15.45%-81.40%SYBXSynlogic+0.68%+1.37%+5.71%+21.31%+0.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AENTOEntero Therapeutics 0.00N/AN/AN/ALSBLakeShore Biopharma 0.00N/AN/AN/ASYBXSynlogic 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$110.87K144.95N/AN/A$5.51 per share0.63ENTOEntero TherapeuticsN/AN/AN/AN/A($2.45) per shareN/ALSBLakeShore Biopharma$614.96M0.03N/AN/A$3.35 per share0.25SYBXSynlogic$10K1,759.68N/AN/A$1.09 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%11/4/2025 (Estimated)ENTOEntero Therapeutics-$18.06MN/A0.00∞N/AN/A-1,063.82%-17.94%11/11/2025 (Estimated)LSBLakeShore Biopharma-$13.93MN/A0.00∞N/AN/AN/AN/A10/30/2025 (Estimated)SYBXSynlogic-$23.36M-$0.08N/AN/AN/AN/A-8.09%-5.50%11/11/2025 (Estimated)Latest ENTO, LSB, SYBX, and AIMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ENTOEntero TherapeuticsN/A-$0.42N/A-$0.21N/AN/A8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/ASYBXSynlogicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.962.882.61ENTOEntero TherapeuticsN/A2.812.81LSBLakeShore Biopharma0.051.020.75SYBXSynlogicN/A3.633.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AENTOEntero Therapeutics12.30%LSBLakeShore Biopharma52.64%SYBXSynlogic63.40%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%ENTOEntero Therapeutics0.75%LSBLakeShore BiopharmaN/ASYBXSynlogic3.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.66 million4.17 millionNot OptionableENTOEntero Therapeutics91.59 million1.58 millionN/ALSBLakeShore Biopharma77320.77 millionN/AN/ASYBXSynlogic8011.70 million11.35 millionOptionableENTO, LSB, SYBX, and AIMD HeadlinesRecent News About These CompaniesSynlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo FinanceJune 28, 2025 | finance.yahoo.comSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSynlogic Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comSynlogic preps phenylketonuria drug for phase 3 after mid-stage winNovember 6, 2024 | pharmaphorum.comPSynlogic, Inc. (0A8U.L)August 24, 2024 | nz.finance.yahoo.comMIN.SG,0P0001I7V6,0 (MIN.SG)August 16, 2024 | nz.finance.yahoo.comMaintaining Hold on Synlogic Amid Strategic Reassessment and Financial UncertaintyAugust 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deSYBX Stock Earnings: Synlogic Beats EPS for Q2 2024August 8, 2024 | investorplace.comSynlogic Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comSynlogic Inc.July 21, 2024 | wsj.comSynlogic Inc SYBXJuly 21, 2024 | morningstar.comMThe Summer Stock Exodus: 3 Companies to Ditch Before the Heat HitsMay 23, 2024 | investorplace.comHold Rating Maintained for Synlogic Amidst Setbacks and Financial UncertaintiesMay 16, 2024 | markets.businessinsider.comSYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | investorplace.comSynlogic, Inc.: Synlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | finanznachrichten.deSynlogic Flat on Q1 NumbersMay 14, 2024 | baystreet.caSynlogic Reports First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Deere’s Sell-Off Could Be a Long-Term Buying ChanceBy Chris Markoch | August 14, 2025ENTO, LSB, SYBX, and AIMD Company DescriptionsAinos NASDAQ:AIMD$3.45 +0.07 (+2.07%) As of 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Entero Therapeutics NASDAQ:ENTO$2.48 +0.16 (+6.90%) Closing price 04:00 PM EasternExtended Trading$2.52 +0.04 (+1.41%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.LakeShore Biopharma NASDAQ:LSB$0.85 +0.01 (+1.55%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Synlogic NASDAQ:SYBX$1.50 +0.04 (+3.01%) Closing price 03:50 PM EasternExtended Trading$1.50 0.00 (-0.27%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
